News >

Examining the Underpinnings of PARP Inhibition in Recurrent Ovarian Cancer

Caroline Seymour
Published: Tuesday, May 28, 2019

Dr NAME – no MD

Gottfried E. Konecny, MD

Whether germline or somatic, patients with recurrent ovarian cancer who harbor BRCA1/2 mutations have shown a unique sensitivity to PARP inhibition. As the field moves forward, optimization of the 3 FDA-approved PARP inhibitors in this setting will come from learning more about the genetic makeup of extreme responders, the features of BRCAness, and the underpinnings of adaptive resistance mechanisms, said Gottfried E. Konecny, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication